(Q44225827)

1 December 2017

title

Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol (English)

1 reference

1 December 2017

0 references

arterial hypertension

1 reference

Karl P Kuhn

1 reference

1 December 2017

Daniel W Byrne

1 reference

1 December 2017

Patrick G Arbogast

1 reference

1 December 2017

Thomas P Doyle

1 reference

1 December 2017

James E Loyd

1 reference

1 December 2017

Ivan M Robbins

1 reference

1 December 2017

language of work or name

English

0 references

publication date

21 November 2002

1 reference

American Journal of Respiratory and Critical Care Medicine

1 December 2017

published in

1 reference

1 December 2017

volume

167

1 reference

1 December 2017

1 reference

1 December 2017

page(s)

580-586

1 reference

Primary pulmonary hypertension. A national prospective study

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Clinical implications of prostaglandin and thromboxane A2 formation (1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Preliminary criteria for the classification of systemic sclerosis (scleroderma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

The 1982 revised criteria for the classification of systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Pulmonary veno-occlusive disease: a case series and new observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Primary pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Systemic sclerosis-associated pulmonary hypertension: short- and long-term effects of epoprostenol (prostacyclin)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200204-333OC

10.1164/RCCM.200204-333OC

21 January 2018

Identifiers

DOI

1 reference

1 December 2017

1 reference